Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice.

Almeida CB, Scheiermann C, Jang JE, Prophete C, Costa FF, Conran N, Frenette PS.

Blood. 2012 Oct 4;120(14):2879-88. doi: 10.1182/blood-2012-02-409524. Epub 2012 Jul 25.

2.

HU for acute treatment of sickle VOC?

El Nemer W.

Blood. 2012 Oct 4;120(14):2777-8. doi: 10.1182/blood-2012-08-447102.

3.

High expression of the cGMP-specific phosphodiesterase, PDE9A, in sickle cell disease (SCD) and the effects of its inhibition in erythroid cells and SCD neutrophils.

Almeida CB, Traina F, Lanaro C, Canalli AA, Saad ST, Costa FF, Conran N.

Br J Haematol. 2008 Sep;142(5):836-44. doi: 10.1111/j.1365-2141.2008.07264.x. Epub 2008 Jun 17.

PMID:
18564357
4.

GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice.

Chang J, Patton JT, Sarkar A, Ernst B, Magnani JL, Frenette PS.

Blood. 2010 Sep 9;116(10):1779-86. doi: 10.1182/blood-2009-12-260513. Epub 2010 May 27.

5.

Nitric oxide and cyclic GMP levels in sickle cell patients receiving hydroxyurea.

Nahavandi M, Tavakkoli F, Wyche MQ, Perlin E, Winter WP, Castro O.

Br J Haematol. 2002 Dec;119(3):855-7.

PMID:
12437671
6.

Leukocyte adhesion and the pathophysiology of sickle cell disease.

Okpala I.

Curr Opin Hematol. 2006 Jan;13(1):40-4. Review.

PMID:
16319686
7.

The fucosylation inhibitor, 2-fluorofucose, inhibits vaso-occlusion, leukocyte-endothelium interactions and NF-ĸB activation in transgenic sickle mice.

Belcher JD, Chen C, Nguyen J, Abdulla F, Nguyen P, Nguyen M, Okeley NM, Benjamin DR, Senter PD, Vercellotti GM.

PLoS One. 2015 Feb 23;10(2):e0117772. doi: 10.1371/journal.pone.0117772. eCollection 2015.

8.

Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation.

Canalli AA, Franco-Penteado CF, Saad ST, Conran N, Costa FF.

Haematologica. 2008 Apr;93(4):605-9. doi: 10.3324/haematol.12119. Epub 2008 Mar 6.

9.
10.

Sickle cell disease: role of reactive oxygen and nitrogen metabolites.

Wood KC, Granger DN.

Clin Exp Pharmacol Physiol. 2007 Sep;34(9):926-32. Review.

PMID:
17645642
11.

Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Lebensburger JD, Howard T, Hu Y, Pestina TI, Gao G, Johnson M, Zakharenko SS, Ware RE, Tuomanen EI, Persons DA, Rosch JW.

Blood. 2012 Feb 23;119(8):1915-21. doi: 10.1182/blood-2011-08-374447. Epub 2011 Nov 30.

12.

Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Manwani D, Frenette PS.

Blood. 2013 Dec 5;122(24):3892-8. doi: 10.1182/blood-2013-05-498311. Epub 2013 Sep 19.

13.

Participation of Mac-1, LFA-1 and VLA-4 integrins in the in vitro adhesion of sickle cell disease neutrophils to endothelial layers, and reversal of adhesion by simvastatin.

Canalli AA, Proença RF, Franco-Penteado CF, Traina F, Sakamoto TM, Saad ST, Conran N, Costa FF.

Haematologica. 2011 Apr;96(4):526-33. doi: 10.3324/haematol.2010.032912. Epub 2010 Dec 20.

14.

Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.

Styles LA, Lubin B, Vichinsky E, Lawrence S, Hua M, Test S, Kuypers F.

Blood. 1997 Apr 1;89(7):2554-9.

15.

Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.

Medicine (Baltimore). 1996 Nov;75(6):300-26.

16.

Inhibition of phosphodiesterase 9A reduces cytokine-stimulated in vitro adhesion of neutrophils from sickle cell anemia individuals.

Miguel LI, Almeida CB, Traina F, Canalli AA, Dominical VM, Saad ST, Costa FF, Conran N.

Inflamm Res. 2011 Jul;60(7):633-42. doi: 10.1007/s00011-011-0315-8. Epub 2011 Feb 20.

PMID:
21336703
17.

Hydroxycarbamide decreases sickle reticulocyte adhesion to resting endothelium by inhibiting endothelial lutheran/basal cell adhesion molecule (Lu/BCAM) through phosphodiesterase 4A activation.

Chaar V, Laurance S, Lapoumeroulie C, Cochet S, De Grandis M, Colin Y, Elion J, Le Van Kim C, El Nemer W.

J Biol Chem. 2014 Apr 18;289(16):11512-21. doi: 10.1074/jbc.M113.506121. Epub 2014 Mar 10.

18.

Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo.

Zennadi R, Moeller BJ, Whalen EJ, Batchvarova M, Xu K, Shan S, Delahunty M, Dewhirst MW, Telen MJ.

Blood. 2007 Oct 1;110(7):2708-17. Epub 2007 Jul 3.

19.

Hydroxyurea therapy in children severely affected with sickle cell disease.

Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.

J Pediatr. 1996 Jun;128(6):820-8.

PMID:
8648542
20.

Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Manwani D, Frenette PS.

Hematology Am Soc Hematol Educ Program. 2013;2013:362-9. doi: 10.1182/asheducation-2013.1.362. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk